IRulya Therapeutics Inc. (IRLA) stock forecast and price target
Price $39.80 · data as of November 13, 2026
12-month price target
Average target$76.12
Upside / downside+91.3%
Analysts8
ConsensusStrong buy
Low $65.00Average $76.12High $98.00
Gold marker: average target · white marker: today’s price ($39.80)
Analyst ratings
Strong buy 2Buy 6Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-5.00 | +98.5% | $0 |
| Next fiscal year ends December 31, 2027 | $-4.66 | +6.8% | $0 |
| Next quarter ends December 31, 2026 | $-1.13 | +99.2% | $0 |
| Quarter after ends March 31, 2027 | $-1.21 | — | $0 |
Consensus of the analysts covering IRulya Therapeutics, updated daily.
Frequently asked questions
What is the IRulya Therapeutics stock price target?
The average 12-month target from 8 analysts is $76.12, 91.3% above the current price of $39.80 Targets range from $65.00 to $98.00.
Is IRulya Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 6 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is IRulya Therapeutics expected to earn?
Analysts expect EPS of $-5.00 for the fiscal year ending December 31, 2026 and $-4.66 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.